Okay, thank you. Some have criticized the 340B program for lack of transparency, including how program savings are used to benefit patients and communities. Many have also said that HRSA has insufficient resources to provide oversight of both manufacturers and covered entities [in the 340B program]. So I believe that we need to increase transparency within the 340B program while ensuring that there's not an undue administrative burden. Ms. Rosenberg, what concerns about transparency and ability to provide oversight has the GAO identified? (02:28–02:38)
CLAIM
Asserts that HRSA lacks sufficient resources for oversight in the 340B program.
This is an excerpt from a raw transcript. The assertions have not been audited or verified. Tap the video to view the source footage and understand the context.
